SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Reports 10 of 47 Frontline AML Patients Advanced to Stem Cell Transplant

Aptevo said 10 of 47 evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine advanced to stem cell transplant.

APVO

Related stories